










doi:10.101Adoptive Immunotherapy with Cytokine-Induced
Killer Cells for Patients with Relapsed Hematologic
Malignancies after Allogeneic Hematopoietic
Cell Transplantation
Ginna G. Laport, Kevin Sheehan, Jeanette Baker, Randall Armstrong,
Ruby M. Wong, Robert Lowsky, Laura J. Johnston, Judith A. Shizuru, David Miklos, Sally Arai,
Jonathan E. Benjamin, Wen-Kai Weng, Robert S. NegrinDonor leukocyte infusions induce remissions in some patients with hematologic malignancies who relapse af-
ter allogeneic hematopoietic cell transplantation (HCT); however, graft-versus-host disease (GVHD) remains
the major complication of this strategy. Cytokine-induced killer (CIK) cells are a unique population of
cytotoxic T lymphocytes that express the CD31CD561 phenotype and show marked up-regulation of the
natural killer cell receptor NKG2D (CD314). CIK cells are non–major histocompatibility complex–restricted
and NKG2D-dependent in target recognition and cytotoxicity. We explored the feasibility of ex vivo expan-
sion of allogeneic CIK cells in patients with relapsed hematologic malignancies after allogeneic HCT. Eighteen
patients (median age, 53 years; range, 20-69 years) received CIK cell infusions at escalating doses of 1  107
CD31 cells/kg (n 5 4), 5  107 CD31 cells/kg (n 5 6), and 1  108 CD31 cells/kg (n 5 8). The median
expansion of CD31 cells was 12-fold (range, 4- to 91-fold). CD31CD561 cells represented a median of
11% (range, 4%-44%) of the harvested cells, with a median 31-fold (range, 7- to 515-fold) expansion. Median
CD31CD3141 cell expressionwas 53% (range, 32%-78%) of harvested cells. Significant cytotoxicity was dem-
onstrated in vitro against a panel of human tumor cell lines. Acute GVHD grade I-II was seen in 2 patients, and
1 patient had limited chronic GVHD. After a median follow-up of 20 months (range, 1-69 months) from CIK
infusion, the median overall survival was 28 months, and the median event-free survival was 4 months. All
deaths were due to relapsed disease; however, 5 patients had longer remissions after infusion of CIK cells
than from allogeneic HCT to relapse. Our findings indicate that this form of adoptive immunotherapy is
well tolerated and induces a low incidence of GVHD, supporting further investigation as an upfront modality
to enhance graft-versus-tumor responses in high-risk patient populations.
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Allogeneic hematopoietic cell transplantation
(HCT) is a curative treatment modality for patients
with malignant diseases. Relapse remains one of
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6/j.bbmt.2011.05.012portends a very poor prognosis. Strategies to induce
remission after relapse include withdrawal of immuno-
suppressive medications and/or donor leukocyte
infusion (DLI). Such approaches attempt to maximize
the graft-versus-tumor effect conferred by donor
T cells. Responses are variable, however, and acute
graft-versus-host disease (GVHD) is a major cause of
treatment failure.
Various forms of adoptive immunotherapy aimed
at reducing the incidence of acute GVHD associated
with DLI have been explored. These approaches have
included escalating doses of T cells, CD81-depleted
DLI, antigen-specific cytotoxic T lymphocytes, and
natural killer (NK) cells [1-3].
Cytokine-induced killer (CIK) cells are cytotoxic
effector T cells that are readily expandable and express
in addition to the T cell marker, CD31, markers1679
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NKG2D. CIK cells are generated by the in vitro cul-
ture of peripheral blood lymphocytes with interferon
(IFN)-g, interleukin (IL)-2, and anti-CD3. T cell ex-
pansion and activation occurs, resulting in cytolytic
cells that recognize targets through NKG2D [4].
NKG2D is an activating receptor expressed on all
NK cells and also serves as a T cell costimulatory mol-
ecule that augments cytotoxic and proliferative
responses of T cells on encountering an antigen
[5,6]. CIK cell–mediated cytotoxicity is major
histocompatibility complex–unrestricted and T cell
receptor–independent, with target killing occurring
through NKG2D-mediated recognition. In preclini-
cal studies, CIK cells have shown potent activity
against several tumor cell lines, with a markedly re-
duced capability to induce GVHD in murine models
[4,7]. CIK cells also have been shown to traffic to
tumor sites, where they persist for 10-14 days and
are associated with a reduced tumor burden. CIK
cells generated from patients with acute myelogenous
leukemia (AML) have demonstrated cytotoxic activity
against both autologous and allogeneic leukemic
blasts [8]. In addition, CIK cells show minimal or no
cytotoxicity against normal tissues including CD341
stem cells, do not suppress marrow engraftment
in vivo, and induce minimal GVHD in allogeneic
models [9]. Compared with CD3-CD561 lymphokine-
activated killer cells, CIK cells have greater potency
against multidrug-resistant tumor cell lines and are
more readily expandable [10]. Because of these attri-
butes demonstrated in murine model systems, using
human cell lines and fresh tumor samples, we devel-
oped conditions for the expansion of CIK cells on
a clinical scale under Good Manufacturing Practice
conditions. We previously reported on the use of
autologous CIK cells [11]. Here we report the results
of a Phase I feasibility study in which escalating doses
of CIK cells derived from HLA-matched sibling
donors were administered to recipients with hemato-
logic malignancies who relapsed after allogeneic HCT.METHODS
Eligibility Criteria
Patients with a hematologic malignancy who had
relapsed disease after undergoing allogeneic HCT
from a matched sibling donor were eligible for this
study. Patients with chronic myelogenous leukemia
were eligible only if persistent disease was demon-
strated after a previous DLI of at least 1 108 cells/kg.
Patients could not have active GVHD and must have
been either receiving no immunosuppressive medica-
tion or taking a stable immunosuppressive regimen.
Adequate organ function was required, as defined by
(1) a serum creatinine level of\2 mg/dL or creatinineclearance of .50 cc/minute and (2) a direct bilirubin
level of\3 mg/dL or transaminase values\3 times
the upper limit of normal. Exclusion criteria included
no active infections. All patients provided written
informed consent before enrollment on this clinical
trial. The study protocol was approved by the Stanford
University Institutional Review Board, and the trial
was conducted in accordance with Declaration of
Helsinki principles.
Study Design
This was a single institution, open-label, Phase I
clinical trial to evaluate the feasibility and safety of al-
logeneicCIK cells. Although efficacywas not a primary
objective of this trial, all patients were followed for ob-
jective outcomes. The hypothesis was that human CIK
cells expanded ex vivo will retain antitumor activity,
but reduce the incidence and severity of GVHD asso-
ciated with unmanipulated DLI. The primary objec-
tives of this trial were to (1) determine the feasibility
of expanding allogeneic CIK cells suitable for clinical
application, (2) determine the infusional toxicity of
ex vivo expanded allogeneic CIK cells in patients
with recurrent or refractory disease after allogeneic
HCT, (3) determine the incidence of GVHD after
infusion of allogeneic CIK cells, and (4) determine
the maximum tolerated dose of allogeneic CIK cell
infusion.
In this dose-escalation study, the starting dose of
CIK cells was 1  107 CD31 cells/kg, followed by
escalation to 5  107 CD31 cells/kg, with a highest
planned dose of 1  108 CD31 cells/kg. In the usual
Phase I design, the plan was to enroll 3 patients at
each cell dose level. If a dose-limiting toxicity (DLT)
was not seen in these 3 patients, then the next higher
cell dose level was administered. If DLT was seen,
then the cohort was expanded to 6 patients. The
dose was increased to 5  107 expanded cells/kg and
1  108 expanded cells/kg in successive escalations
based on the absence of significant infusional or other
toxicities or GVHD. To progress to the next dose
level, there must have been no grade 3 or greater
toxicities as defined by the Common Toxicity Criteria
and no evidence of acute GVHD beyond grade II.
Donor Apheresis and CIK Cell Expansion
In each case, the matched sibling donor who had
donated the graft for the earlier allogeneic HCT was
used as the CIK cell donor. The donors underwent
unmobilized apheresis, and up to 1 L of autologous
plasma was collected from each donor to supplement
the expansion culture. Sufficient quantities of cells
(.1.6  109) were collected to allow inoculation of
the CIK cell expansion cultures. The cultures were
inoculated on the same day as collection, with a mini-
mumof 6.0 108 cells and amaximumof 7.5 108 cells
Biol Blood Marrow Transplant 17:1679-1687, 2011 1681Cytokine-Induced Killer Cellsadded to Aim-V medium (Invitrogen, Grand Island,
NY) and supplemented with 5% autologous (donor)
heat-inactivated plasma and 2  105 IU IFN-g
(Actimmune; InterMune, Brisbane, CA) in a continu-
ous perfusion biochamber maintained at 37 with
20% O2 and 5% CO2. During the initial culture acti-
vation period, medium perfusion did not occur. This
continuous perfusion culture was performed for the
first 11 patients, and gas-permeable culture bags
were used for all patients thereafter.
On the next day (day 11), expansion was initiated
with muronmab-CD3 (Orthoclone, OKT3; Orthobio-
tech, Raritan, NJ) at 50 ng/mL and IL-2 (Proleukin;
Chiron, Emeryville, CA) at 300 IU/mL. Both agents
were added to the continuous perfusate of the bio-
chamber with AimV medium containing 5% inacti-
vated autologous plasma and 300 U/mL of IL-2 at
a rate of 0.104 mL/minute, equivalent to 150 mL/
day. This rate of medium flow resulted in a 50% ex-
change of the culture volume each day. To assess the
accuracy of the perfusion rate, the cultures were sam-
pled on every third day of culture beginning on day
14, and lactate levels were measured as indicators of
culture health. If the lactate level measured was
.0.8 mg/mL (9 mM), the medium perfusion rate
was increased according to prespecified guidelines
until the lactate level dropped to\0.8 mg/mL. The
period of expansion with IL-2 was maintained for
21-28 days. The static culture bags were fed every
2-3 days, and the volume was increased as needed to
maintain the cell density at 2-4  106/mL.
Samples were removed from each culture bag for
detection of Mycoplasma by polymerase chain reaction
at 5 days before harvest. Additional samples were
drawn from each bag after the final addition ofmedium
and IL-2 at 3 days before culture harvest for sterility
testing of bacterial and fungal contaminants. On the
day of harvest, samples were removed for final release
tests, including white blood cell count and viability,
Gram staining, endotoxin testing, and T cell content
determination. Sterility testing was performed by the
Stanford Hospital Clinical Microbiology Laboratory.Culture Conditions and Culture Harvest
Cultures were maintained in either Aastrom
Replicell biochambers (Aastrom Biosciences, Ann
Arbor, MI) or Baxter LifeCell culture bags (Baxter
Healthcare, Deerfield, IL) at 37C and 5% CO2 over
21-28 days, as indicated. Cultures for patients 1-11
were expanded in Aastrom Replicell biochambers
modified to allow 10-15 L of medium perfusion per
biochamber over the duration of the culture. Each
biochamber was inoculated with 750  106 peripheral
blood cells collected by apheresis and cytokines added
as described earlier. On day 14 of incubation, contin-
uous perfusion of the culture began with fresh mediumsupplemented with IL-2 at 300 IU/mL. The infusion
rate was gradually increased over the course of the cul-
ture based on lactic acid levels in medium perfused
from the biochambers. Cultures for patients 12-18
were expanded in LifeCell culture bags once the
Aastrom Replicell biochambers were discontinued
for this potential indication. Cultures were inoculated
in multiple 1-L LifeCell bags, each containing 200 mL
of medium with 4  108 peripheral blood cells. Cyto-
kines were added as described earlier. On day 14 and
every third day thereafter, cultures were assessed for
cell density and viability. Additional culture medium
supplemented with sufficient IL-2 to maintain $300
IU IL-2/mL was added to LifeCell bags to adjust
cell density to $2  106 and 4  106 viable cells/mL.
If cell density did not require additional volume,
then IL-2 alone was added at 300 IU/mL of culture
volume. When bag volume exceeded 500 mL, the
contents were transferred to a 3-L LifeCell bag and
maintained as before until harvest.
After 21 or 28 days, cells cultured in biochambers
were collected in an Aastrom cell processor and
washed with Normosol-R (pH 7.4; Baxter Healthcare,
Deerfield, IL) supplemented with 1% human serum
albumin (CLS Behring, King of Prussia, PA or
Telacris, Research Triangle Park, NC). Cells cultured
in LifeCell bags were pooled, volume-reduced, and
washed with Normosol plus 1% haemophilus selective
agar. Harvested cells were concentrated to 200-300
mL for infusion and maintained at ambient tempera-
ture until infusion. Cells were infused within 6 hours
of harvest and were not cryopreserved.
Samples also were obtained for phenotyping and
cytotoxicity assessments. The infused cell dose was
based on total CD31 cell content and adjusted to the
cohort dose.Cell Analysis and Cytotoxicity Assays
Cell counts were performed on an impedance
counter (Beckman Coulter, Brea, CA) and viability
by Trypan blue exclusion. Cell phenotypes were
assessed by flow cytometry of inoculating cells and
harvested cell cultures using monoclonal antibodies
to CD3 (clone HIT-3a) and CD56 (clone NCAM)
for CIK cell enumeration. Additional phenotyping
included CD4 (clone RPA-T4), CD8 (clones HIT-
8A and SK1), and CD314 (clone 1D11). CD3141
designates KLRK1, the gene encoding NKG2D.
Killing of target cell lines, including SUDHL-4,
OCI-Ly8, DB, and Jurkat, by CIK cell cultures for
patients 1-16 was assessed by chromium release assays
as described previously [11]. For patients 17 and 18,
cytotoxicity against the target cell lines was assessed
using the ApoLogix carbofluorescein polycaspase
detection assay (Cell Technology, Mountain View,
CA) according to the manufacturer’s directions.
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CIK cells harvested from the expansion cultures
and meeting the release criteria were infused within
6 hours of harvest. The cells were infused through
a central venous catheter or peripheral intravenous
line of at least 18 gauge and were infused over a period
of 30 minutes. Electrocardiogram tracings were
obtained before the CIK cell infusion, and vital signs
were monitored every 30 minutes after infusion for
at least 2 hours.
Study Assessments
Postinfusion toxicity evaluations were performed
in the outpatient setting on days 11, 13, 17 114,
121, and156. Variable number tandem repeat analy-
sis was performed before infusion and at days17,121,
and156 after infusion of CIK cells. Positron emission
tomography scanning and/or bone marrow biopsy
evaluation were performed at regular intervals after
CIK cell infusion to assess clinical responses. These
tests were performed on days 130 and 160, at a
minimum, after CIK infusion.RESULTS
Patient Characteristics
Eighteen patients received CIK cell infusions
at 3 dose levels (Table 1). The median age was
53 years (range, 20-69 years). Diagnoses included non-
Hodgkin lymphoma (NHL; n 5 5), AML (n 5 3),
multiple myeloma (MM; n 5 3), chronic lymphocytic












1 1 39 AML ABL 3 ME
2 1 52 NHL RIC 8 Pre
3 1 45 APL RIC 3 DL
4 1 33 NHL ABL 140 IFR
5 2 55 MM RIC 3 Bor
6 2 44 MM RIC 20 Tha
7 2 28 HD RIC 11 Bor
8 2 45 MDS ABL 12 HiD
9 2 60 MM RIC 24 Tha
10 2 52 NHL RIC 18 Lym
11 3 55 AML ABL 29 ME
12 3 56 NHL RIC 6 Lym
13 3 57 CLL RIC 24 No
14 3 69 CLL RIC 30 XR
15 3 53 ALL ABL 42 Ima
16 3 53 NHL RIC 3 RTX
17 3 20 ALL ABL 9 HC
18 3 68 MDS RIC 3 No
ABL indicates myeloablative; MEC, mitoxantrone, etoposide, and cytarabine; I
MOPP, mechlorethamine, vincristine, procarbazine, and prednisone; HiDAC
cyclophosphamide, vincristine, doxorubicin, and dexamethasone; PD, progres
*This patient had persistent disease after allogeneic HCT.(ALL; n 5 2), myelodysplastic syndrome (MDS;
n 5 2), and Hodgkin’s disease (HD; n 5 1). All
patients had relapsed after allogeneic HCT using
a matched sibling donor. Twelve patients had received
a reduced-intensity conditioning (RIC) regimen, and
6 patients had received a myeloablative regimen. The
median time from HCT to relapse was 12 months
(range, 3-142 months), and the median time from
relapse to CIK infusion was 4 months (range, 1-34
months). With the exception of 1 patient with CLL
and 1 patient with MDS, all patients received some
form of cytoreductive therapy (including chemother-
apy, corticosteroids, surgical resection, or DLI) before
CIK infusion. At the time of CIK infusion, 10 patients
(56%) were in complete remission (CR), 4 patients
were in partial remission (PR), 1 patient with acute
promyelocytic leukemia (APL) had amolecular relapse
that failed to respond to DLI, and 3 patients had
progressive disease.Cell Characterization and Expansion
Table 2 specifies the viability and cell counts of the
18 harvested products after expansion and activation
that were prepared under Good Manufacturing Prac-
tice conditions. The median viability of the cultured
products was 86.5% (range, 70%-95%) with a median
12-fold (range, 4- to 91-fold) expansion of CD31 cells
and a median 31-fold (range, 7- to 515-fold) expansion
of CD31CD561 cells. The median CD31CD3141-
or NKG2D-expressing population was 53% (range,
32%-78%). Figure 1 is a contour plot from the prod-
uct of a donor, depicting the expansion of CD31 cellsTreatment before CIK
Time from
Relapse to CIK,
Months Disease Status at CIK
C 1 CR3
dnisone 2 CR3
I  2 10 Molecular relapse
T throat 4 CR3
tezimib/dex, thal/dex 11 PD/refractory
l/dex 9 PR2
tezimib, MOPP, gemcitabine 5 CR3
AC + idarubicin 2 CR3
l/dex 14 PD/refractory/2 relapse
ph node resection 2 CR3
C 3 CR2




, XRT 34 CR4
VAD  2, XRT 4 CR2
ne * PD
FRT, involved field radiotherapy; dex, dexamethasone; thal, thalidomide;
, high-dose cytarabine; XRT, radiotherapy; RTX, rituximab; HCVAD,
sive disease.
Table 2. Cell Expansion and Characterization
Total Harvested Cells Median Range
Viability 87% 70%-95%
% CD3+ cells 97% 46%-100%
CD3+ cell count 7.5  109 1.9  109-1.2  1010
CD3 fold expansion 12 4-91
% CD3+CD56+ 11% 4%-44%
CD3+CD56+ cell count 1.2  109 2.9  108-6.2  109
CD3+CD56+ fold expansion 31 7-515
% CD3+CD314+ 53% 32%-78%
CD3+CD314+ cell count 5.4  109 1.5  109-1.2  1010
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culture period.
Cytotoxicity assays were performed with the ex-
panded CIK cells against 4 tumor targets: SUDHL-4,
OCI-Ly8, DB, and Jurkat. Approximately 40%-60%
specific killing at an effector-target ratio of 40:1 was
observed against all 4 cell lines, with the greatest per-
centage of killing seen against Jurkat, a T cell leukemia
target (Figure 2). Because of ineffective 51Cr labeling
or lack of cell expansion, cytotoxicity was not assessed
in all donors against all 4 cell lines. The numbers of
donors tested against each cell line were 16 for
SUDHL-4, 17 for OCI-Ly8, 15 for DB, and 16 for
Jurkat.Figure 1. Fluorescence-activated cell sorting analysis of peripheral blood mo
number of cells expressing CD31C561 and CD31CD3141 phenotypes.CIK Administration and Clinical Responses
The CIK cell doses administered based on
CD31cells/kg were 1  107 in 4 patients, 5  107 in
6 patients, and 1  108 in 8 patients. The median
follow-up duration from the time of CIK infusion
was 20 months (range, 1-69 months), and the median
event-free survival (EFS) and overall survival (OS)
from the time of CIK infusion were 4 months and 28
months, respectively. Of the 12 patients who received
CIK cells while in CR, 11 patients relapsed, with a me-
dian time to relapse of 6 months (range, 2-37 months).
Patient 3 had a molecular relapse of APL at day 193
after nonmyeloablative HCT. She had previously re-
ceived 2 DLI infusions without response. This patient
achieved a molecular response approximately 4 weeks
after CIK infusion. The median follow-up time for
all patients from relapse after allogeneic HCT was
29 months, (range, 5-74 months), whereas the median
EFS and OS from the time of relapse after allogeneic
HCT were 13 months and 37 months, respectively.
Table 3 summarizes patient outcomes.
Of the 18 patients enrolled on this trial, 5 achieved
or maintained CR for more than 1 year after CIK infu-
sion, with 1 patient remaining in CR at 32 months after
CIK infusion. Four of these 5 patients had a lymphoid
malignancy, and 1 patient had AML. The patient withnonuclear cells after 21 days of culture, illustrating the increase in the
Figure 2. (A) In vitro cytotoxic activity of CIK cells by specific tumor target. Killing of target cell lines including SUDHL-4, OCI-Ly8, DB, and Jurkat at an
E:Tratio of 40:1. (B) In vitro cytotoxic activity of CIK cells by each patient against 4 tumor targets—SUDH-L4, OCI-Ly8, DB, and Jurkat—at an E:Tratio
of 40:1.
1684 Biol Blood Marrow Transplant 17:1679-1687, 2011G. G. Laport et al.the longest CR after CIK infusion was a 33-year-old
man with multiply relapsed mantle cell lymphoma.
This patient underwent myeloablative allogeneic
HCT in 1995 while in second CR. Twelve years later,
he had an isolated relapse in a supraglottic node, for
which he received involved field radiation therapy
followed by CIK infusion. At the time of this report,
he had maintained CR for 32 months. Another notable
case was a 39-year-old man with primary refractory
AML who relapsed 3 months after myeloablative
allogeneic HCT. He received salvage chemotherapyfollowed by CIK infusion. His remission lasted 20
months until disease relapse, and he died soon after. A
long-term remission was seen in a 56-year-old woman
who underwent autologous HCT in 1995 for relapsed
diffuse large cell lymphoma (DLCL). She relapsed 3
years later and received salvage chemotherapy followed
by RIC allogeneic HCT. She experienced relapse in the
left axilla 5 months later, and underwent an excisional
biopsy followed byCIK infusion. She subsequently sus-
tained a CR for 37 months. A 68-year-old woman with
MDS received a CIK infusion approximately 6 months
Table 3. Patient Outcomes
Patient
Dose
Level Diagnosis Best Response
Time from
CIK to Relapse Alive
Cause of




1 1 AML CR 19 months No Relapse 21
2 1 NHL PR/SD 13 months No Relapse 30
3 1 AML CR 4 months No Relapse Ventricular arrhythmia
grade 4
46
4 1 NHL CR/SD Remission Yes 32
5 2 MM PD 9 days No Relapse 1
6 2 MM CR 6 months No Relapse Ventricular arrhythmia
grade 3, ALT grade 3
28
7 2 HD CR 6 months Yes Chronic limited 70
8 2 MDS CR 4 months No Relapse Acute grade 2 skin 13
9 2 MM PD 9 days No Relapse 14
10 2 NHL CR 12 months Yes 59
11 3 AML CR 2 months No Relapse Grade 3 ALT, AST 24
12 3 NHL CR/SD 37 months Yes 43
13 3 CLL SD 2 months Yes 20
14 3 CLL PD 15 days Yes 18
15 3 ALL CR/SD 2 months Yes 18
16 3 NHL CR/SD 10 months Yes 13
17 3 ALL CR/SD 8 months Yes Acute grade 2 skin,
hepatic
9
18 3 MDS CR Remission Yes 3
PD indicates progressive disease; SD, stable disease; ALT, alanine aminotransferease; AST, aspartate aminotransferase.
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bone marrow biopsy performed at 3 months after
CIK infusion showed no evidence of MDS.
Four patients (2 with MM and 2 with CLL) pro-
gressed rapidly within 2 months after CIK infusion.
All 4 of these patients had active disease at the time
of CIK infusion despite receiving cytoreductive ther-
apy before CIK infusion.
With a median follow-up time of 20 months
(range, 1-69 months) for all patients, 10 patients are
alive at the time of this report. Of these, 2 remain
disease-free and 8 are alive with relapsed disease after
CIK infusion. Eight patients have died, with progres-
sive disease being the primary cause of death.
Chimerism and Serum Immunophenotyping
Eleven patients retained full donor chimerism after
relapse from allogeneic HCT, and their status did not
change after CIK infusion. Five patients exhibited
mixed donor chimerism (defined by .5% and\95%
CD31 cells) at the time of CIK infusion. Of these 5 pa-
tients, 1 patient with MDS who had mixed chimerism
with 82% donor CD31 chimerism at the time of CIK
infusion converted to full donor chimerism showing
100% CD31 cells at approximately 2 months after
CIK infusion. This patient received the highest CIK
dose level. The mixed donor chimerism status of the
other 4 patients remained stable. Chimerism data
was not obtained on 2 patients.
GVHD and Adverse Events
Acute GVHD occurred in 2 patients. One of these
patients, at the second dose level, developed grade IIskin GVHD at approximately 98 days after CIK infu-
sion. The GVHD resolved with topical corticosteroids
alone. At the third dose level, 1 patient developed grade
II hepatic GVHD with a concomitant skin rash on the
trunk and bilateral upper extremities at approximately
7 weeks after CIK infusion. A skin biopsy and liver
biopsy were performed, and results from both organs
were equivocal for either GVHD or a drug reaction.
The patient was treated with corticosteroids, tacroli-
mus, and mycophenolate mofetil and achieved partial
resolution of GVHD. Chronic GVHD occurred in
only 1 patient. This patient developed limited chronic
GVHD on day 1123 after CIK infusion, manifesting
as joint stiffness and aching that responded to oral
corticosteroids, which were eventually discontinued.
One patient at the first dose level experienced
a transient grade 3 ventricular arrhythmia that resolved
spontaneously without intervention during CIK cell
infusion. At the second dose level, 1 patient also
experienced syncope at approximately 3 weeks after
CIK infusion. A comprehensive investigation of the
etiology of the syncope revealed inducible sustained
ventricular tachycardia during cardiac electrophysio-
logic studies, which led to placement of an implantable
defibrillator at 1 month after CIK infusion. The dys-
rhythmia did not recur after placement of the device.
This patient also experienced a transient rise in hepatic
transaminase levels that resolved without intervention.
Because of these 2 DLTs, the cohort was expanded to
a total of 6 patients. No other DLTs were seen at this
dose level, and thus we proceeded to the third dose
level of 1  108 CD31 cells/kg. To date, 8 patients
have been infused at this dose, and no DLTs have
been observed in these patients.
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Relapse remains one of the leading causes of treat-
ment failure after allogeneic HCT and typically carries
a poor prognosis. DLI is a strategy offered to relapsed
patients in this situation, but this form of adoptive
immunotherapy can incur significant toxicity, with
acute GVHD and marrow aplasia as the leading causes
of nonrelapse mortality after DLI [12]. Furthermore,
although DLI has been extremely effective in treating
chronic myelogenous leukemia, this treatment modal-
ity has been less effective in the treatment of other
hematologic malignancies [13-15].
Our Phase I study demonstrated the feasibility and
safety of allogeneic CIK cell infusions in patients with
relapsed hematologic malignancies. This Phase I
dose-escalation trial reached a planned maximum cell
dose of 1  108 CD31 cells/kg as the maximum toler-
ated dose. We observed only 2 cases of grade II acute
GVHD that responded to topical or systemic cortico-
steroids and 1 case of limited chronic GVHD. The
most serious adverse events seen were at the lowest
cell dose. Two patients developed transient ventricular
dysrhythmias, the etiology of which was not elucidated.
The low incidence of GVHD in this clinical study
parallels the low incidence seen in preclinical models.
We previously demonstrated that the adoptive transfer
of allogeneic CIK cells in a rodent model induced min-
imal GVHD [9]. Using bioluminescence imaging, we
showed that luciferase-expressing CIK cells generated
from splenocytes exhibited traffic patterns similar to
those of conventional T cells. However, compared
with the conventional T cells, the CIK cells infiltrated
GVHDtarget tissuesmuch less, demonstrated a slower
division rate, were less susceptible to apoptosis, and
produced high amounts of IFN-g, a cytokine known
to confer a protective effect against acute GVHD [16].
Because this was a Phase I feasibility study in a very
heterogeneous patient population, it is difficult to
draw conclusions regarding efficacy. In the 12 patients
who received CIK infusions while in CR, the median
time to progression was 6 months. This duration of re-
mission is notable, considering that this was a high-risk
population with the most durable remissions observed
in patients with lymphoid malignancies. From the
time of CIK infusion, the median EFS and OS were
4 months and 28 months, respectively. Although al-
most all of the patients in this study underwent some
form of cytoreduction before CIK infusion, 5 patients
had a longer time to progression/relapse after CIK in-
fusion compared with the time to progression/relapse
immediately after allogeneic HCT. CIK cell infusion
had no affect on patients with rapidly progressive dis-
ease at the time of infusion. The affect of CIK infusion
on donor chimerism could not be assessed in most
patients, because 11 patients already exhibited full do-
nor chimerism at the time of CIK infusion. However,1 of 5 patients with mixed chimerism converted to
full donor chimerism by approximately 2 months after
CIK infusion without the development of GVHD.
A previous Phase I study of similar design also de-
scribed clinical responses in patients who had received
allogeneic CIK infusions after post-HCT relapse.
Introna et al. [17] administered allogeneic CIK infu-
sions in 11 patients with hematologic malignancies
and reported CR in 3 patients, with 1 remission lasting
for more than 2 years at the time of the report. Two of
the 3 patients with CR converted to full donor chime-
rism but also developed extensive cutaneous GVHD
that commenced shortly after the documented clinical
response. Unlike our study, in which patients received
only 1 CIK cell infusion, most patients received
multiple sequential infusions, with cell doses ranging
from 3  106 to 15  106 CD31 cells/kg.
In terms of feasibility of culture and expansion, we
generated a median 12-fold expansion of CD31 cells
and 31-fold expansion of CD31CD561 cells, similar
to the expansion data reported by Introna et al. [17].
In addition, we characterized the percentage and
number of CD31CD3141 cells, with 53% of cells
expressing this phenotype after culture. We also
confirmed in vitro antitumor activity against various
tumor targets, as reported previously by our group
and others [9,17,18].
Other groups have manipulated CIK cells with the
intent of improving specificity and enhancing cytotox-
icity against various tumor targets. The cytotoxicity of
CIK cells was significantly increased against B-NHL
targets when cocultured with the anti-CD20 anti-
bodies, rituximab, and GA101 [19]. Other investiga-
tors have incorporated bispecific antibodies with the
goal of redirecting CIK cells and increasing killing
against primary ovarian cancer cells and against
B cell ALL [20,21]. The expansion of cord blood–
derived CIK cells represents another promising
source of adoptive immunotherapy with potential
application for patients with relapsed malignancies
after umbilical cord blood transplantation [22]. We
also have used CIK cells to deliver an oncolytic virus
to the tumor bed in a preclinical model with remark-
able efficacy [23]. This approach is being developed
for clinical translation.
In conclusion, the present study shows the feasibil-
ity and safety of allogeneic CIK cell infusion in patients
with relapsed hematologic malignancies. Although
CIK cells require expansion under specific culture
conditions, we and other groups have demonstrated
the feasibility of this approach and have obtained
similar results in terms of low observed toxicity and
high cell yields. Although assessing clinical responses
in this setting is difficult given the variable and high-
risk nature of this patient population, it should be
noted that several responses extended past 1 year in
this high-risk patient population. As seen with DLI,
Biol Blood Marrow Transplant 17:1679-1687, 2011 1687Cytokine-Induced Killer CellsCIK cells appear to induce the longest duration of
response in patients who had minimal residual disease
at the time of infusion. Determining the comparable
efficacy of CIK cells and DLI in the setting of relapse
is difficult, but our data and those of others have
confirmed lengthy clinical responses accompanied by
a low incidence of acute and chronicGVHD compared
with DLI [17]. Thus, our results suggest that CIK cells
exert a biological effect and warrant further investiga-
tion. We are currently conducting 2 follow-on studies
with CIK cell infusion after allogeneicHCTwith RIC.
One of these studies involves high-risk patients with
MDS who received CIK cells preemptively on day
142, and a second trial is open to patients with CLL
who demonstrate mixed chimerism. In this second
trial, both chimerism and molecular disease burden
will be assessed.ACKNOWLEDGMENTS
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